COVID-19 大流行期间患有风湿病的儿童和青少年的风险意识、幸福感、抑郁和焦虑--德国 KICK-COVID 前瞻性多中心研究的结果

IF 2.8 3区医学 Q1 PEDIATRICS

Pediatric Rheumatology Pub Date : 2024-04-18 DOI:10.1186/s12969-024-00979-z

Claudia Sengler, Jens Klotsche, Malthe Jessen Pedersen, Martina Niewerth, Julia Göldel, Daniel Windschall, Johannes-Peter Haas, Frank Dressler, Ralf Trauzeddel, Anton Hospach, Frank Weller-Heinemann, Stefanie Lanzinger, Clemens Kamrath, Reinhard W. Holl, Petra Warschburger, Kirsten Minden

{"title":"COVID-19 大流行期间患有风湿病的儿童和青少年的风险意识、幸福感、抑郁和焦虑--德国 KICK-COVID 前瞻性多中心研究的结果","authors":"Claudia Sengler, Jens Klotsche, Malthe Jessen Pedersen, Martina Niewerth, Julia Göldel, Daniel Windschall, Johannes-Peter Haas, Frank Dressler, Ralf Trauzeddel, Anton Hospach, Frank Weller-Heinemann, Stefanie Lanzinger, Clemens Kamrath, Reinhard W. Holl, Petra Warschburger, Kirsten Minden","doi":"10.1186/s12969-024-00979-z","DOIUrl":null,"url":null,"abstract":"To investigate the psychosocial burden in children and adolescents with juvenile rheumatic diseases during the COVID-19 pandemic. As part of the multicentre observational KICK-COVID study linked to the National Pediatric Rheumatology Database, adolescents < 21 years and parents of children < 12 years with rheumatic diseases answered questions on perceptions of health risk (PHR) due to SARS-CoV2, stress, well-being (WHO-5) and symptoms of depression (PHQ-9) and anxiety (GAD-7). Data were collected at routine visits from June to December 2021 and assessed for association with demographic and clinical parameters, treatment and patient-reported outcomes by multivariable regression analyses. Data from 1356 individuals (69% female, 50% adolescents) were included. Median PHR on a numeric rating scale (NRS, 0–10) was 4 (IQR 2–6), median perceived stress was 3 (IQR 1–6). Adolescents reported a worse well-being with a significantly lower median WHO-5-score (60, IQR 40–76) than parents reported for their children < 12 years (80, IQR 68–84). Moderate to severe symptoms of depression and anxiety were reported by 14.3% and 12.3% of the adolescents, respectively. PHR was significantly higher in patients with systemic lupus erythematosus, methotrexate or biologic disease-modifying anti-rheumatic drug therapy than in patients without these characteristics, whereas lower WHO-5 or higher PHQ-9 or GAD-7 scores were only associated with poorer patient-reported health status and physical functioning. The perception of health risk due to SARS-CoV2 infection was not paralleled by an impairment of mental health, which were, however, significantly correlated with self-rated health status and functional capacity, highlighting the importance of patient-reported outcome assessment. German Clinical Trials Register (DRKS), no. DRKS00027974. Registered on 27th of January 2022.","PeriodicalId":54630,"journal":{"name":"Pediatric Rheumatology","volume":"28 1","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk perception, well-being, depression and anxiety in children and adolescents with rheumatic diseases during the COVID-19 pandemic - results from the prospective multicenter KICK-COVID study in Germany\",\"authors\":\"Claudia Sengler, Jens Klotsche, Malthe Jessen Pedersen, Martina Niewerth, Julia Göldel, Daniel Windschall, Johannes-Peter Haas, Frank Dressler, Ralf Trauzeddel, Anton Hospach, Frank Weller-Heinemann, Stefanie Lanzinger, Clemens Kamrath, Reinhard W. Holl, Petra Warschburger, Kirsten Minden\",\"doi\":\"10.1186/s12969-024-00979-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To investigate the psychosocial burden in children and adolescents with juvenile rheumatic diseases during the COVID-19 pandemic. As part of the multicentre observational KICK-COVID study linked to the National Pediatric Rheumatology Database, adolescents < 21 years and parents of children < 12 years with rheumatic diseases answered questions on perceptions of health risk (PHR) due to SARS-CoV2, stress, well-being (WHO-5) and symptoms of depression (PHQ-9) and anxiety (GAD-7). Data were collected at routine visits from June to December 2021 and assessed for association with demographic and clinical parameters, treatment and patient-reported outcomes by multivariable regression analyses. Data from 1356 individuals (69% female, 50% adolescents) were included. Median PHR on a numeric rating scale (NRS, 0–10) was 4 (IQR 2–6), median perceived stress was 3 (IQR 1–6). Adolescents reported a worse well-being with a significantly lower median WHO-5-score (60, IQR 40–76) than parents reported for their children < 12 years (80, IQR 68–84). Moderate to severe symptoms of depression and anxiety were reported by 14.3% and 12.3% of the adolescents, respectively. PHR was significantly higher in patients with systemic lupus erythematosus, methotrexate or biologic disease-modifying anti-rheumatic drug therapy than in patients without these characteristics, whereas lower WHO-5 or higher PHQ-9 or GAD-7 scores were only associated with poorer patient-reported health status and physical functioning. The perception of health risk due to SARS-CoV2 infection was not paralleled by an impairment of mental health, which were, however, significantly correlated with self-rated health status and functional capacity, highlighting the importance of patient-reported outcome assessment. German Clinical Trials Register (DRKS), no. DRKS00027974. Registered on 27th of January 2022.\",\"PeriodicalId\":54630,\"journal\":{\"name\":\"Pediatric Rheumatology\",\"volume\":\"28 1\",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12969-024-00979-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12969-024-00979-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

摘要

调查COVID-19大流行期间患有幼年风湿病的儿童和青少年的社会心理负担。作为与全国儿科风湿病学数据库相连接的多中心观察性 KICK-COVID 研究的一部分，年龄小于 21 岁的青少年和年龄小于 12 岁的风湿病患儿的父母回答了有关 SARS-CoV2 导致的健康风险认知（PHR）、压力、幸福感（WHO-5）以及抑郁症状（PHQ-9）和焦虑症状（GAD-7）的问题。这些数据是在 2021 年 6 月至 12 月的例行就诊中收集的，并通过多变量回归分析评估了这些数据与人口统计学和临床参数、治疗和患者报告结果之间的关联。研究纳入了 1356 人（69% 为女性，50% 为青少年）的数据。按数字评分量表（NRS，0-10）计算的患者健康状况报告中位数为 4（IQR 2-6），感知压力中位数为 3（IQR 1-6）。青少年报告的健康状况较差，WHO-5 评分中位数（60，IQR 40-76）明显低于家长报告的 12 岁以下儿童的健康状况（80，IQR 68-84）。分别有 14.3% 和 12.3% 的青少年出现中度至重度抑郁和焦虑症状。接受过系统性红斑狼疮、甲氨蝶呤或生物改良抗风湿药物治疗的患者的PHR明显高于未接受过这些治疗的患者，而较低的WHO-5或较高的PHQ-9或GAD-7评分仅与患者报告的较差的健康状况和身体功能有关。SARS-CoV2感染导致的健康风险感知与心理健康受损并不同步，但心理健康受损与自评健康状况和功能能力显著相关，这凸显了患者报告结果评估的重要性。德国临床试验注册中心（DRKS），编号：DRKS00027974。DRKS00027974.注册日期：2022 年 1 月 27 日。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Risk perception, well-being, depression and anxiety in children and adolescents with rheumatic diseases during the COVID-19 pandemic - results from the prospective multicenter KICK-COVID study in Germany

To investigate the psychosocial burden in children and adolescents with juvenile rheumatic diseases during the COVID-19 pandemic. As part of the multicentre observational KICK-COVID study linked to the National Pediatric Rheumatology Database, adolescents < 21 years and parents of children < 12 years with rheumatic diseases answered questions on perceptions of health risk (PHR) due to SARS-CoV2, stress, well-being (WHO-5) and symptoms of depression (PHQ-9) and anxiety (GAD-7). Data were collected at routine visits from June to December 2021 and assessed for association with demographic and clinical parameters, treatment and patient-reported outcomes by multivariable regression analyses. Data from 1356 individuals (69% female, 50% adolescents) were included. Median PHR on a numeric rating scale (NRS, 0–10) was 4 (IQR 2–6), median perceived stress was 3 (IQR 1–6). Adolescents reported a worse well-being with a significantly lower median WHO-5-score (60, IQR 40–76) than parents reported for their children < 12 years (80, IQR 68–84). Moderate to severe symptoms of depression and anxiety were reported by 14.3% and 12.3% of the adolescents, respectively. PHR was significantly higher in patients with systemic lupus erythematosus, methotrexate or biologic disease-modifying anti-rheumatic drug therapy than in patients without these characteristics, whereas lower WHO-5 or higher PHQ-9 or GAD-7 scores were only associated with poorer patient-reported health status and physical functioning. The perception of health risk due to SARS-CoV2 infection was not paralleled by an impairment of mental health, which were, however, significantly correlated with self-rated health status and functional capacity, highlighting the importance of patient-reported outcome assessment. German Clinical Trials Register (DRKS), no. DRKS00027974. Registered on 27th of January 2022.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatric Rheumatology PEDIATRICS-RHEUMATOLOGY

CiteScore

4.10

自引率

8.00%

发文量

审稿时长

>12 weeks

期刊介绍： Pediatric Rheumatology is an open access, peer-reviewed, online journal encompassing all aspects of clinical and basic research related to pediatric rheumatology and allied subjects. The journal’s scope of diseases and syndromes include musculoskeletal pain syndromes, rheumatic fever and post-streptococcal syndromes, juvenile idiopathic arthritis, systemic lupus erythematosus, juvenile dermatomyositis, local and systemic scleroderma, Kawasaki disease, Henoch-Schonlein purpura and other vasculitides, sarcoidosis, inherited musculoskeletal syndromes, autoinflammatory syndromes, and others.